How does MKM compare to Chinese Peptide Company on documentation quality?

The particulars: MKM · Chinese Peptide Company.

I am trying to choose between two options that are usually discussed as though only one exists.

I am not optimising for price, but I am not indifferent to it either.

What does each option buy me, and what does it cost me?

The relevant detail is that the structural problem with a group buy is that the organiser typically holds both the money and the material, which means there is no point at which any participant has recourse. That is solvable, and it is solved by design rather than by trust.

What a verification listing at VendorInvestigate or a rating at PeptideMeter actually evidences is that some process was applied — which is more than nothing and considerably less than an audit. The useful question is what the process consists of and whether its inputs are independently obtained samples or vendor-supplied ones.

Concretely, personal-importation discretion varies more than people assume. Several jurisdictions operate a published enforcement-discretion policy for small quantities for personal use of unapproved products; several do not, and treat any importation of an unapproved medicinal product as an offence irrespective of quantity. The distinction is jurisdiction-specific and worth checking rather than inferring from a forum consensus.

The limitation of the red-flag approach is that it is asymmetric: it identifies bad documentation reliably and good material only weakly.

Structure the group buy so that no single person is simultaneously the treasurer, the custodian and the arbiter. That one change removes most of the failure modes.

Put another way, cost per milligram is the wrong denominator until you have adjusted for dead-space loss, content shortfall and the cost of the testing you will do. After that adjustment the ranking often changes.

The diagnostic red flags, in rough order of how much they tell you: a certificate whose lot number does not match the vial; a certificate with no method section; a purity figure quoted to two decimal places with no chromatogram; a testing date that precedes the stated manufacturing date; identical certificates across nominally different lots; and "sterile filtered" offered in place of a sterility test. Each of those is a specific inference, not a vibe.

To be exact about it, the consumer-protection question about a stablecoin transfer has a simple answer: you give up reversibility entirely. There is no chargeback, no acquirer, no dispute process. What you retain is the on-chain record, which proves that a transfer happened and to which address — useful for establishing that you paid, useless for getting the money back. That asymmetry is the whole risk profile.

Regulatory positions on personal importation are published: the relevant frameworks are the US FDA’s personal importation policy in its Regulatory Procedures Manual, the UK MHRA’s guidance on importing medicines for personal use, and the equivalent national provisions in the EU member states and Australia’s Therapeutic Goods Administration personal importation scheme. They differ materially from each other.

The evidence you want is boring: the same result, from an independent laboratory, across more than one lot, over more than one year.

edited 15 Aug 2024 by ayo_fadipe — added the method parameters

The question to ask is not whether a vendor is good but what evidence exists, of what kind, about which lots, from whom. Reputation is a compression of that evidence and it compresses badly.

Cost per milligram, worked honestly: a 10 mg vial at £34 is £3.40 per nominal milligram. If the content assay says 9.2 mg, that is £3.70 per actual milligram. If you then lose 4 µL of dead space per draw from a 2 mL fill across twenty draws, that is 80 µL or four per cent of the fill, taking you to £3.85. Add a £110 content assay amortised across the vial and it is £14.85 per milligram for the first vial of a new lot and £3.85 thereafter. The testing dominates, which is the actual argument for buying larger lots.

The economics of pooled purchasing are not specific to this field, and the failure modes documented in the general literature on informal collective purchasing — organiser default, quality dispute without adjudication, and free-riding on testing costs — are exactly the ones that recur here.

Worth being explicit that this site sells nothing, is not affiliated with any supplier, and has no financial relationship with any vendor discussed. Vendor storefronts are linked from the vendor directory, marked nofollow and sponsored.

If a supplier will not send you a lot-specific certificate before you order, you have learned something useful at zero cost.

Evaluate a supplier on the documentation they cannot fabricate cheaply, which in practice means lot-specific certificates from a laboratory that hosts its own reports and a testing history that spans more than one lot.

Lot-to-lot content variation of nine per cent between two nominally identical lots, both within a stated specification, is the single most common finding in independent testing and the least discussed. It is not fraud; it is the consequence of a fill process controlled to a tolerance rather than to a target. It is also the reason a per-lot content assay is worth more than a per-supplier reputation.

Where VendorInvestigate has documented verification processes, the value is in the audit trail rather than in the badge, and reading the process description is more informative than reading the outcome.

Assume no recourse and plan accordingly. That assumption is both prudent and, in this context, accurate.

edited 17 Jul 2024 by RP_C18 — corrected a unit error in the worked example